Antiplatelet medicines for psoriasis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests whether antiplatelet medicines (like aspirin and clopidogrel) can help control psoriasis or psoriatic arthritis. If you have one of these skin or joint conditions and are generally healthy, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 89 years old.
- You need a confirmed diagnosis of psoriasis or psoriatic arthritis from a doctor.
- You must not have had a heart attack, stroke, or blocked leg arteries in the past.
- You must be willing to stop any blood thinners for at least 2 weeks before starting.
- You must not have severe bleeding problems, stomach ulcers, or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
This trial tests an experimental drug called FT2109 for people with psoriatic arthritis, a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if FT2109 can reduce symptoms and improve quality of life.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study tests an oral investigational pill (CBP-0276) called an oral therapy for psoriatic arthritis. The goal is to see if it reduces joint pain, swelling, and psoriasis symptoms better than a placebo (inactive pill).
This study tests an experimental drug called JNJ-88545223 to see if it can reduce joint pain, swelling, and skin plaques in people with active psoriatic arthritis. It may help if you have both joint symptoms and psoriasis.
This trial tests an investigational drug (DDY391) in people with moderate to severe psoriatic arthritis. The goal is to see how well it works and if it is safe, which might help reduce joint pain and skin symptoms.
Hear when a new Psoriasis (PsO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.